Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Drug Name | SL-172154 |
Trade Name | |
Synonyms | SL172154|SL 172154|CD172a-Fc-CD40L Chimeric Protein SL-172154 |
Drug Descriptions |
SL-172154 is a fusion protein that is engineered to target CD47 on tumor cells and CD40 on antigen presenting cells (APCs), which inhibits CD47/SIRPa signaling and potentially results in increased anti-tumor immune response (NCI Drug Dictionary). |
DrugClasses | |
CAS Registry Number | NA |
NCIT ID | C173706 |
Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
---|---|---|---|
Azacitidine + SL-172154 | Azacitidine SL-172154 | 0 | 1 |
Azacitidine + SL-172154 + Venetoclax | Azacitidine SL-172154 Venetoclax | 0 | 1 |
Mirvetuximab Soravtansine + SL-172154 | Mirvetuximab Soravtansine SL-172154 | 0 | 1 |
Pegylated liposomal doxorubicin + SL-172154 | Pegylated liposomal doxorubicin SL-172154 | 0 | 1 |
SL-172154 | SL-172154 | 0 | 3 |
SL-172154 + Venetoclax | SL-172154 Venetoclax | 0 | 0 |